<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="; font-style : italic;} Lancet Infect DisLancet Infect DisThe Lancet." exact="Infectious" post="Diseases1473-30991474-4457Elsevier Ltd. pmcid: 7158580S1473-3099(20)30123-7 doi: 10.1016/S1473-3099(20)30123-7 : Personal View"/>
 <result pre="Infectious Diseases1473-30991474-4457Elsevier Ltd. pmcid: 7158580S1473-3099(20)30123-7 doi: 10.1016/S1473-3099(20)30123-7 : Personal View" exact="Disease" post="X: accelerating the development of medical countermeasures for the"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="coordinated subject matter experts to create a preparedness plan for" exact="Disease" post="X. Disease X is caused by Pathogen X, an"/>
 <result pre="matter experts to create a preparedness plan for Disease X." exact="Disease" post="X is caused by Pathogen X, an infectious agent"/>
 <result pre="Disease X. Disease X is caused by Pathogen X, an" exact="infectious" post="agent that is not currently known to cause human"/>
 <result pre="the rapid development of medical countermeasures for Pathogen X, an" exact="infectious" post="agent currently unknown to cause human disease, but with"/>
 <result pre="X: a pathogen that is previously unknown to cause human" exact="disease" post="but possesses epidemic or pandemic potential. â€¢There are key"/>
 <result pre="X Pathogen X could be any pathogen including but not" exact="limited" post="to viruses, bacteria, fungi, parasites, or prions. Of the"/>
 <result pre="viruses, bacteria, fungi, parasites, or prions. Of the 400 emerging" exact="infectious disease" post="events recorded since 1940, bacteria (including rickettsia) account for"/>
 <result pre="bacteria, fungi, parasites, or prions. Of the 400 emerging infectious" exact="disease" post="events recorded since 1940, bacteria (including rickettsia) account for"/>
 <result pre="recorded since 1940, bacteria (including rickettsia) account for 54%, whereas" exact="viral" post="or prion pathogens (25%), protozoa (11%), fungi (6%), and"/>
 <result pre="(11%), fungi (6%), and helminths (3%) are less common.2 Although" exact="viral" post="pathogens represent a small proportion of the pathogens that"/>
 <result pre="a small proportion of the pathogens that account for emerging" exact="infectious disease" post="events, the most devastating recent emergence eventsâ€&quot;namely, HIV, influenza"/>
 <result pre="small proportion of the pathogens that account for emerging infectious" exact="disease" post="events, the most devastating recent emergence eventsâ€&quot;namely, HIV, influenza"/>
 <result pre="devastating recent emergence eventsâ€&quot;namely, HIV, influenza H1N1 and H5H1, severe" exact="acute" post="respiratory syndrome coronavirus, Lassa virus, Ebola virus, and Middle"/>
 <result pre="recent emergence eventsâ€&quot;namely, HIV, influenza H1N1 and H5H1, severe acute" exact="respiratory" post="syndrome coronavirus, Lassa virus, Ebola virus, and Middle East"/>
 <result pre="emergence eventsâ€&quot;namely, HIV, influenza H1N1 and H5H1, severe acute respiratory" exact="syndrome" post="coronavirus, Lassa virus, Ebola virus, and Middle East respiratory"/>
 <result pre="respiratory syndrome coronavirus, Lassa virus, Ebola virus, and Middle East" exact="respiratory" post="syndrome coronavirusâ€&quot;have involved RNA viruses.3, 4 They can replicate"/>
 <result pre="syndrome coronavirus, Lassa virus, Ebola virus, and Middle East respiratory" exact="syndrome" post="coronavirusâ€&quot;have involved RNA viruses.3, 4 They can replicate in"/>
 <result pre="these pathogens have an opportunity to cross species and establish" exact="localised" post="emergence. A synergy of enhanced virulence and population dynamics"/>
 <result pre="can hypothesise that the advent of a catastrophic outbreak involving" exact="Disease" post="X is likely to result from the zoonotic transmission"/>
 <result pre="types of pathogens of pandemic importance, but the work on" exact="Disease" post="X that we have done is modelled on the"/>
 <result pre="of medical countermeasures does not demand that the epidemiology of" exact="Disease" post="X is known, and many conserved elements of product"/>
 <result pre="epidemiology. In the first instance, development of medical countermeasures for" exact="Disease" post="X will inevitably include plans to detect cases and"/>
 <result pre="of influenza samples. Although the Pandemic Influenza Preparedness Framework is" exact="limited" post="by its inability to address sharing of pathogen genetic"/>
 <result pre="based. Opportunities for accelerating the development of medical countermeasures against" exact="Disease" post="X The product development cycle remains lengthy for de-novo"/>
 <result pre="typically take 2â€&quot;5 years to develop and 5â€&quot;10 years to" exact="complete" post="development, before procurement can be initiated. The timeline for"/>
 <result pre="times of diagnostics, vaccines, clinical trials, and small molecules for" exact="Disease" post="X (table 1 ). Technological opportunities speed up discovery"/>
 <result pre="pathogens. The database can be expanded by proactively researching new" exact="infectious" post="agents in animals and humans. Develop broad-spectrum and narrow-spectrum"/>
 <result pre="and standardised animal models Standardise and validate animal models of" exact="disease" post="transmission and pathogenesis that are sufficient for research and"/>
 <result pre="for animal-use protocols and interpretation of study results. Insufficient standardised" exact="viral" post="stock strains hinder preclinical research and manufacturing processes Empower"/>
 <result pre="rapidly synthesise nucleotide sequences or even to predictively stockpile vaccine-ready" exact="viral" post="seeds. Clinical trials Few standardised clinical protocol designs Standardise"/>
 <result pre="planning and study design (eg, incidence and clinical characterisation of" exact="disease" post="in symptomatic populations). Ensure that master clinical trial protocols"/>
 <result pre="study design (eg, incidence and clinical characterisation of disease in" exact="symptomatic" post="populations). Ensure that master clinical trial protocols that are"/>
 <result pre="and indication. Protocol development is a separate activity under the" exact="Epidemic" post="Preparedness Research and Development Blueprint.22, 23 Loosely coordinated clinical"/>
 <result pre="confidence that the platform can be successfully applied to prevent" exact="disease" post="from a new pathogen. Such platforms include plug-and-play recombinant"/>
 <result pre="currently only be addressed through empirical testing. The Coalition for" exact="Epidemic" post="Preparedness Innovation is funding development of several RNA-based and"/>
 <result pre="assays that can discriminate between the immune response to active" exact="infections" post="or past exposure will also be important. These antibody-dependent"/>
 <result pre="of approved substrates could reduce the time required to develop" exact="stable" post="cell lines and achieve better yield, capacity, and costs."/>
 <result pre="We suggest that the first step after the identification of" exact="Disease" post="X is the development of a global intervention target"/>
 <result pre="by funders or oversight bodies, or both, with input from" exact="disease" post="and product development experts, to provide clear guidance to"/>
 <result pre="minimum and optimistic targets. The minimum target sets the absolute" exact="lower" post="bound of acceptable product attributes, whereas optimistic targets can"/>
 <result pre="can then create integrated product development plans that outline the" exact="complete" post="scope of manufacturing as well as clinical and regulatory"/>
 <result pre="would be listed on the product label (eg, prevention of" exact="disease" post="vs reduction in disease severity or duration). Consider how"/>
 <result pre="the product label (eg, prevention of disease vs reduction in" exact="disease" post="severity or duration). Consider how the product could be"/>
 <result pre="is cure or prevention possible, as opposed to reduction of" exact="disease" post="severity? Target population Which age groups are the target"/>
 <result pre="on the basis of the epidemic response and control strategy" exact="Epidemic" post="or pandemic potential of the pathogen (eg, virulence, latency,"/>
 <result pre="natural history, biology, pathogenesis, and genetics of the pathogen (eg," exact="viral" post="life cycle, entry mechanisms, hosts, genomic sequence); mechanism of"/>
 <result pre="and standardised animal models that recapitulate the pathogenesis of human" exact="disease" post="to do efficacy studies Correlation of animal and human"/>
 <result pre="sites, sample size, control groups) including clinical endpoints (survival vs" exact="disease" post="prevention) Expertise of clinical trial sites, capacity, disease incidence"/>
 <result pre="(survival vs disease prevention) Expertise of clinical trial sites, capacity," exact="disease" post="incidence or epidemiology studies; established infrastructure (including patient recruitment"/>
 <result pre="product development space in epidemic response. These challenges are particularly" exact="acute" post="when the target population is located in an area"/>
 <result pre="exist that derive human efficacy data from animal surrogates or" exact="intermediate" post="clinical endpoints, and provide considerable scientific and agency support.36,"/>
 <result pre="assist in reducing the time to manufacture licensed products for" exact="infectious diseases," post="and aim to improve coordination and understanding of the"/>
 <result pre="including the use of animal surrogates for human efficacy and" exact="intermediate" post="endpoints or biomarkers. Conclusion Our intent for this Personal"/>
 <result pre="pathogen-agnostic, and low-risk opportunities enable the best near-term preparedness for" exact="Disease" post="X. We also advocate for the use of iTPPs"/>
 <result pre="1KanerJSchaackSUnderstanding Ebola: the 2014 epidemicGlobal Health1220165327624088 2JonesKEPatelNGLevyMAGlobal trends in emerging" exact="infectious" post="diseasesNature451200899099318288193 3RauchSJasnyESchmidtKEPetschBNew vaccine technologies to combat outbreak situationsFront Immunol92018196330283434"/>
 <result pre="RNA viruses: a case study of the biology of emerging" exact="infectious" post="diseasesMicrobiol Spectr12013 6Kreuder JohnsonCHitchensPLSmiley EvansTSpillover and pandemic properties of"/>
 <result pre="zoonoses for global health capacity buildingâ€&quot;themes from One Health Zoonotic" exact="Disease" post="Workshops in 7 countries, 2014â€&quot;2016Emerg Infect Dis232017 9KellyTRKareshWBJohnsonCKOne Health"/>
 <result pre="to influenza vaccines: global health diplomacy and the controversies surrounding" exact="avian influenza" post="H5N1 and pandemic influenza H1N1PLoS Med72010e100024720454566 13collab: Secretariat of"/>
 <result pre="on biological diversityhttps://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf2014 14KnaufSAbelLHallmaier-WackerLKThe Nagoya protocol and research on emerging" exact="infectious" post="diseasesBull World Health Organ97201937931210672 15collab: WHOWHO R&amp;amp;D Blueprint meeting"/>
 <result pre="vaccine technologies: essential components of an adequate response to emerging" exact="viral" post="diseasesJAMA31920181431143229566112 19collab: Johns Hopkins Center for Health SecurityVaccine platforms:"/>
 <result pre="to support development and production of health technologies for priority" exact="infectious diseases" post="with epidemic potentialhttps://www.who.int/medicines/ebola-treatment/R-D-Blueprint_Evaluation-of-platform-technologies-for-priority-patho.pdf?ua=12016 21MaruggiGZhangCLiJUlmerJBYuDmRNA as a transformative technology for"/>
 <result pre="21MaruggiGZhangCLiJUlmerJBYuDmRNA as a transformative technology for vaccine development to control" exact="infectious" post="diseasesMol Ther27201975777230803823 22collab: WHOInterVax Tool: decision support for vaccine"/>
 <result pre="Engineering &amp;amp; Biotechnology NewsA small-footprint, integrated, and automated platform for" exact="viral" post="productionhttps://www.genengnews.com/resources/tutorial/a-small-footprint-integrated-and-automated-platform-for-viral-production/ 24collab: WHOGood participatory practice guidelines for trials of"/>
 <result pre="effective protein therapy in large animalsMol Ther2320151456146426050989 27collab: Coalition for" exact="Epidemic" post="Preparedness InnovationsCEPI launches new call for innovative platform technologies"/>
 <result pre="new call for innovative platform technologies to rapidly respond to" exact="Disease" post="Xhttps://cepi.net/news_cepi/cepi-launches-new-call-for-innovative-platform-technologies-to-rapidly-respond-to-disease-x/2019 28collab: Coalition for Epidemic Preparedness InnovationsOur platform technologyhttps://cepi.staging.tegu.hexdigital.com/research_dev/technology/"/>
 <result pre="technologies to rapidly respond to Disease Xhttps://cepi.net/news_cepi/cepi-launches-new-call-for-innovative-platform-technologies-to-rapidly-respond-to-disease-x/2019 28collab: Coalition for" exact="Epidemic" post="Preparedness InnovationsOur platform technologyhttps://cepi.staging.tegu.hexdigital.com/research_dev/technology/ 29NayakSBlumenfeldNRLaksanasopinTSiaSKPoint-of-care diagnostics: recent developments in"/>
 <result pre="We thank the subject matter experts and members of the" exact="Disease" post="X Working Group who gave their time and extensive"/>
</results>
